ReviewBrain, behavior, & immunity - health2026
Immune dysregulation and neuroinflammation in bipolar disorder: Pathophysiological insights and therapeutic perspectives.
Review in Brain, behavior, & immunity - health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Flavonoids as Modulators of Neuroinflammation in Affective Disorders: A Narrative Review.International journal of molecular sciences · 2026Review
- Integrated Chemometric and Machine Learning Analysis Identifies Peripheral Biosignatures Distinguishing Major Depressive Disorder from Bipolar Disorder: A Translational Cross-Sectional Study.Medicina (Kaunas, Lithuania) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bipolar disorder (BD) is increasingly associated with immune system dysregulation encompassing both peripheral and central components. Peripheral low-grade inflammation, marked by elevated proinflammatory cytokines and impaired anti-inflammatory responses, contributes to systemic immune imbalance in BD. This peripheral inflammatory state may compromise blood-brain barrier (BBB) integrity, facilitating the entry of peripheral immune mediators into the central nervous system (CNS) and triggering neuroinflammatory cascades. Within the CNS, neuroinflammation is orchestrated primarily by microglial and astrocytic activation, which disrupts neuronal homeostasis and synaptic function. Additionally, oxidative stress acts as a crucial mediator, exacerbating neuronal damage. Based on current findings, this review synthesises evidence linking both central and peripheral inflammation to the pathophysiology of BD, offering a perspective on its underlying biology. A comprehensive understanding of the dynamic interplay between peripheral inflammation and central neuroimmune responses is essential for identifying novel therapeutic targets and developing interventions that effectively address both systemic and CNS components of BD pathophysiology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.